# BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

> **NCT01957735** · PHASE1 · COMPLETED · sponsor: **BPGbio** · enrollment: 97 (actual)

## Conditions studied

- Metastatic Cancer
- Cancer
- Solid Tumor

## Interventions

- **DRUG:** BP31510 monotherapy
- **DRUG:** BP31510 in combination with chemotherapy

## Key facts

- **NCT ID:** NCT01957735
- **Lead sponsor:** BPGbio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2017-02-01
- **Final completion:** 2017-02-01
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957735, "BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01957735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*